

MacroCap SP and MacroCap Q

ION EXCHANGE CHROMATOGRAPHY

MacroCap™ SP (a cation exchanger) and MacroCap Q (an anion exchanger) are designed for the purification of large biomolecules such as polyethylene glycol (PEG)-modified proteins (i.e., PEGylated proteins) that are intended for use as biopharmaceuticals.

PEGylation typically changes a native protein sample into a mixture of native protein and much larger-sized PEG-protein conjugates of varied PEG-to-protein mole ratios. Because PEG is neutral, such conjugates exhibit lower average surface charge. In post-PEGylation purification steps, these two factors (larger size and lower charge) adversely affect capacity and resolution (1). These factors also contribute to fouling of the medium (resin), thereby reducing media lifetime. MacroCap SP and MacroCap Q (Fig 1) have characteristics that help to reduce such effects.

MacroCap SP and MacroCap Q provide:

- High purity and yield of PEGylated proteins at high sample loads
- Good stability allowing for scalable use from laboratory to production

Medium characteristics

Designed to separate large biomolecules

MacroCap SP and MacroCap Q are based on Cytiva's proprietary media with mass transfer properties suitable for large biomolecules. The base matrix is highly porous, which gives high available surface area for adsorption of large molecules. The basic characteristics of the two media are shown in Table 1.

High purity and yield at high sample load

MacroCap SP and MacroCap Q are designed to separate PEGylated and other large biomolecules. It allows separation of mono- from oligo- and non-PEGylated proteins with high selectivity under high



Fig 1. MacroCap SP and MacroCap Q can be used to purify PEGylated and other large biomolecules to high purity and yield at high sample loads. Robust chemical stability helps ensure long media lifetimes.

load conditions. Figure 2 shows the separation of cytochrome C modified with 20 000 M_r PEG on MacroCap SP, at a sample load of 6 mg protein/mL medium. The dynamic binding capacity ($Q_{B10\%}$) for mono-PEGylated cytochrome C was 3.8 mg/mL. A similar analysis for MacroCap Q is presented in Figure 3.

Since PEGylation generally involves pure native protein, the economic value of the product is typically very high. Thus good recovery of target PEGylated protein is of primary importance for overall productivity. The results show that based on absorbance, 99% of the mono-PEGylated protein could be recovered from MacroCap SP at a purity by size analysis of 93%.

The large pore size also makes MacroCap SP suitable for binding other large proteins. Figure 4 compares binding of IgM (M_r 750 000) to MacroCap SP and SP Sepharose™ High Performance.

Table 1. Key characteristics of MacroCap SP and MacroCap Q

Matrix	Cross-linked copolymer of allyl dextran and N,N-methylene bisacrylamide	
Ion exchange type	MacroCap SP, strong cation; MacroCap Q, strong anion	
Charged group		
MacroCap SP	-SO ₃ ⁻	
MacroCap Q	-N(CH ₂) ₃ ⁺	
Total ionic capacity		
MacroCap SP	0.10 to 0.13 mmol H ⁺ /mL medium	
MacroCap Q	0.07 to 0.10 mmol Cl ⁻ /mL medium	
Particle size [†]	50 µm (d _{50v})	
Flow velocity	120 cm/h in BPG™ 300, 20 cm bed height or 70 cm/h in BPG 300, 30 cm bed height using process buffers with the same viscosity as water at < 3 bar (0.3 MPa)	
Recommended separation range	a) Proteins in excess of 150 000 M _r b) Functionalized dextrans or PEGs greater than or equal to 20 000 M _r c) PEGylated proteins containing greater than or equal to 10 000 M _r of PEG (total) per conjugate	
pH stability [‡]	MacroCap SP	MacroCap Q
short-term	2 to 13	1 to 12
working	3 to 12	3 to 11
long-term	4 to 11	3 to 10
Storage temperature	4°C to 30°C	
Chemical stability	All commonly-used aqueous buffers, 0.5 M NaOH, 0.1 M citric acid, 25% ethanol, 30% propanol, 30% methanol, 50% ethylene glycol, 1% Tween-20, and 1% SDS	
Binding capacity [§]	> 50 ^a mg BSA/mL medium > 8 ^b /13 ^c mg 30 kDa PEGylated BSA/mL medium	

[†] d_{50v} is the medium particle size of the cumulative volume distribution.

[‡] Short-term pH: pH interval where the medium can be subjected to cleaning-in-place or sanitization-in-place (accumulated 90 to 400 h at room temperature) without significant change in function.

Working pH: pH interval where the medium binds protein as intended or that needed for elution without adverse long-term effect.

Long-term pH: pH interval where the medium can be operated without significant change in function.

[§] For MacroCap Q, dynamic binding capacity at 10% breakthrough measured in a Tricorn 5/100 column with 10 cm bed height at a residence time of:

a) 10 min (60 cm/h) in 10 mM phosphate, pH 7.0, conductivity 1.5 mS/cm

b) 10 min (60 cm/h) in approximately 20 mM phosphate, pH 7.0, conductivity 2.9 mS/cm

c) 33 min (18 cm/h) in approximately 7 mM phosphate, pH 7.0, conductivity 1.0 mS/cm

Good chemical stability and long medium lifetime

Both media have good chemical stability, which allows cleaning-in-place (CIP) to be performed both at acidic and alkaline conditions. The hydrophilic nature of the base matrix reduces nonspecific binding and reduces fouling issues that may be experienced with more hydrophobic base matrices. Together these features assure long medium lifetime.

Figure 5 shows that the selectivity and binding capacity of MacroCap SP for RNase A, cytochrome C, and lysozyme were unchanged after 30 cycles of CIP involving acidic and alkaline conditions in each cycle.

Column: Tricorn™ 5/100 (bed height 107 mm; column volume [CV] 2.1 mL) packed with MacroCap SP

Sample: Cytochrome C modified with 20 000 M_r PEG

Sample load: 6 mg total protein per mL medium


Buffer A: 0.02 M sodium phosphate, pH 6.8

Buffer B: Buffer A + 0.4 M sodium chloride

Flow rate: 0.2 mL/min (61 cm/h)

Gradient: 0% to 100% Buffer B in 20 CV

System: ÄKTAexplorer™ 10

**Fig 2.** PEGylated cytochrome C[†] separated on MacroCap SP.

(A) Chromatograms of the separation. Fractions that were pooled for the size exclusion chromatography (SEC) analysis are indicated in blue and numbered.

(B) Pooled fractions indicated in (A) were analyzed by SEC on Superdex™ 200 for the amounts of oligo-, mono-, and non-PEGylated proteins.

[†] Bovine cytochrome C (Sigma Aldrich, USA) covalently modified with monomethoxy-PEG 20 000 succinimidylpropionic acid (SPA) reagent (Nektar Therapeutics, USA).

Column: Tricorn 5/100 (bed height 96 mm; column volume (CV) 1.9 mL) packed with MacroCap Q

Sample: Reaction mixture[†] with bovine serum albumin (BSA) modified with 30 000 M_r PEG in 20 mM phosphate buffer pH 6.5

Sample load: 1 mg total protein per mL medium

Buffer A: 20 mM phosphate buffer, pH 7.0


Buffer B: Buffer A + 500 mM NaCl, pH 7.0

Flow rate: 0.33 mL/min (100 cm/h)

Gradient: 0% to 40% Buffer B in 20 CV followed by 100% B for 5 CV

System: ÄKTAexplorer 100

[†] Bovine serum albumin (Sigma Aldrich, A9430) covalently modified with 30 000 M_r maleimide-PEG reagent (NOF, Sunbright ME-300MA).

**Fig 3.** PEGylated bovine serum albumin on MacroCap Q. (A) Chromatogram of the separation. Fractions that were analyzed by SEC are indicated in blue and numbered. (B) Fractions indicated in (A) were analyzed by SEC on Superdex 200 for the amounts of PEGylated protein, non-PEGylated protein and PEGylation reaction byproducts.

Column: Tricorn 5/100 packed with either (A) MacroCap SP or (B) SP Sepharose High Performance (CV 2 mL)

Sample: IgM (human), 96% pure by HPLC

Sample load: 0.5 mg/mL medium

Buffer A: 100 mM sodium acetate, pH 4.75

Buffer B: Buffer A + 0.5 M sodium chloride

Flow rate: 0.3 mL/min (90 cm/h)

Gradient: 0% to 100% Buffer B in 20 CV

System: ÄKTAexplorer 10




Fig 4. Binding and elution of a pure (96% by HPLC) sample of IgM ($M_r = 750\,000$) (Sigma Aldrich, USA) on (A) MacroCap SP and (B) SP Sepharose High Performance. The large pore structure of MacroCap SP gives it a greater capability to bind large biomolecules.

Column: MacroCap SP in 10 mm i.d., 9 cm bed height column (CV 7.1 mL)

Sample: 0.5 mg/mL RNase A, 0.5 mg/mL cytochrome C and 0.5 mg/mL lysozyme

Sample load: 1 CV

Buffer A: 20 mM phosphate buffer at pH 6.8

Buffer B: Buffer A + 0.4 M NaCl

Flow rate: 1 mL/min (75 cm/h)

Gradient: 0% to 100% Buffer B in 15 CV

System: ÄKTAexplorer 100




Fig 5. CIP study of MacroCap SP. The performance of MacroCap SP in the separation of RNase A, cytochrome C, and lysozyme was unaffected following 30 cycles of a CIP procedure. CIP conditions per cycle: 5 column volumes (CV) H_2O , 2 CV 0.5 M NaOH followed by 40 min static contact, 2 CV H_2O , 2 CV acidic solution ($\sim pH\,2$) followed by 40 min static contact, 2 CV H_2O , 5 CV 0.5 M NaOH followed by 40 min static contact, and 5 CV H_2O .

Meets industrial needs

MacroCap SP and MacroCap Q are Cytiva BioProcess™ media, specifically designed to meet the demands of industrial biotechnology. This means that the medium is scalable from laboratory to production, is produced with validated manufacturing procedures, and can withstand standard CIP and sanitization-in-place procedures. In addition, BioProcess media are supported with regulatory support files and comprehensive documentation, as well as security of supply service.

Operation and method development for PEGylated proteins

How PEGylation affects protein purification

PEGylation changes a native protein into a much larger-sized PEG-protein conjugate of lower average surface charge. By weight, PEG polymers typically occupy over six times the hydration volume of globular proteins. Both effects (larger size and lower surface charge) increase with the degree of PEGylation. Consequently, the dynamic binding capacity (mg of protein per mL gel) of an ion exchange medium for PEGylated proteins, compared with native proteins, can decrease by a factor of about 10. In a typical ion exchange gradient run with a PEGylation reaction mixture, the products will elute in the following order: free PEG substances, oligo-PEGylated proteins, mono-PEGylated proteins, and non-PEGylated proteins.

During sample loading, proteins with higher surface charge will often displace those with lower charge, and non-PEGylated proteins exhibit some capacity to displace PEGylated proteins at higher sample loading. Ease of displacement is related to the degree of PEGylation and other factors such as solution conductivity. As a result, greater loading may contribute to higher target purity in such situations.

The above factors suggest that loading PEGylation reaction mixtures using buffers with a conductivity that promotes flow through of non-target PEGylated proteins, and optimal binding of target and non-PEGylated proteins, will make better use of column capacity.

Development and optimization

The aim of designing and optimizing a method for the separation of large biomolecules, such as PEGylated proteins, is to ensure high and consistent binding capacity and selectivity, enabling robust and scalable operation.

MacroCap SP and MacroCap Q operate as normal ion exchangers. They have been designed for large-scale operation, and allow flow velocities of 120 cm/h at 20 cm bed height in a 30 cm i.d. column (70 cm/h at 30 cm bed height). These are common operating flow velocities for processing of large, slowly diffusing biomolecules. A faster flow may be possible with lower bed heights. Note, however, that residence times of 6 to 15 min are recommended to fully exploit the properties of the medium, mainly because larger molecules diffuse slower and require more time to bind to the medium.

Method development can be done in small columns, such as Tricorn columns. A detailed purification protocol is given in the instruction manual. In addition to reducing protein charge density, PEGylation may alter protein pI by 1 unit or more. As a result it is suggested to experiment with adsorption at lower than normal pH and conductivity.

The difference in performance between various ion exchange media for large biomolecules may not be evident at low sample loadings. However, at high sample loadings, the greater capacity and resolution properties of MacroCap SP and MacroCap Q become evident, as do reduced fouling and other properties that make MacroCap ion exchangers the media of choice to purify large biomolecules, including PEGylated proteins.

Scale-up

Laboratory methods can be scaled up using small-diameter columns and working up to the final intended large-scale column height and linear flow rate (residence time). Scale-up can be continued by increasing column diameter. Table 1 lists flow rates and other recommendations to consider when scaling up the use of MacroCap SP and MacroCap Q. Reducing bed height will often allow for the use of a significantly greater flow rate.

Cleaning-in-place

Stability studies have demonstrated that MacroCap SP resists typical CIP conditions at both low and high pH. Note that specific CIP protocols should be developed according to the feedstock applied and other related operating conditions.

Summary

MacroCap SP and MacroCap Q are ion exchangers designed to purify PEGylated and other large biomolecules, at high sample loads. Mono-PEGylated proteins can be separated to high purity from oligo-PEGylated and non-PEGylated proteins in a single run. Both media are scalable from laboratory to production, are produced with validated manufacturing procedures, and can withstand standard CIP and sanitization-in-place procedures.

Reference

1. Fee, C. J. and Van Alstine, J. M. PEG-proteins: Reaction engineering and separation issues. *Chem. Eng. Sci.* **61**, 924–939 (2006).

Ordering information

Product, media	Pack size [†]	Code number
MacroCap SP	25 mL	17-5440-10
MacroCap SP	100 mL	17-5440-01
MacroCap SP	1 L	17-5440-02
MacroCap SP	5 L	17-5440-03
MacroCap Q	25 mL	17-5469-01
MacroCap Q	500 mL	17-5469-02
MacroCap Q	5 L	17-5469-04

[†] Larger quantities are available. Please contact Cytiva for more information.

Literature	Code number
Ion Exchange Chromatography & Chromatofocusing: Principles and Methods	18-0004-21

cytiva.com/protein-purification

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. ÄKTAexplorer, BioProcess, BPG, MacroCap, Sepharose, Superdex, and Tricorn are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

© 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit cytiva.com/contact

CY13472-23Jul20-DF

